CervoMed Reports Early 12-Week Biomarker Decline in nfvPPA Phase 2a Trial
CervoMed reported initial 12-week biomarker data from its open-label Phase 2a trial of neflamapimod in nonfluent variant primary progressive aphasia, presented October 12, 2026 at the ISFTD annual meeting. The average plasma neurofilament light chain level declined, but the trial has 25 participants and no placebo or control group during the open-label period, so the results are early. The filing contains no revenue or financial results, and the company expects 24-week biomarker data in November 2026 and topline clinical data in the first quarter of 2027.
Key points
- Mean plasma NfL change was about -3.1 pg/mL over the first 12 weeks across 25 participants, with most of the decline between weeks six and 12.
- In an exploratory subgroup with baseline NfL at or above the median (n=13), mean NfL change was about -5.7 pg/mL over 12 weeks; GFAP levels were stable.
- One patient met protocol criteria for discontinuation due to elevated liver enzymes; the company reported no new safety signals.
- 24-week biomarker data will be presented at CTAD in November 2026; clinical data are expected in the first quarter of 2027.
The filing
Written by AI on Nov 9, 2026, 8:28 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 13, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.